

RXFP3 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP19132b**Specification**

RXFP3 Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [Q9NSD7](#)**RXFP3 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 51289**Other Names**

Relaxin-3 receptor 1, RLN3 receptor 1, G protein-coupled receptor SALPR, G-protein coupled receptor GPCR135, Relaxin family peptide receptor 3, Somatostatin- and angiotensin-like peptide receptor, RXFP3, RLN3R1, SALPR

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

RXFP3 Antibody (C-term) Blocking Peptide - Protein Information**Name** RXFP3**Synonyms** GPCR135, RLN3R1, SALPR**Function**

Receptor for RNL3/relaxin-3. Binding of the ligand inhibit cAMP accumulation.

Cellular Location

Cell membrane; Multi-pass membrane protein.

Tissue Location

Expressed predominantly in brain regions. Highest expression in substantia nigra and pituitary, followed by hippocampus, spinal cord, amygdala, caudate nucleus and corpus callosum, quite low level in cerebellum. In peripheral tissues, relatively high levels in adrenal glands, low levels in pancreas, salivary gland, placenta, mammary gland and testis

RXFP3 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

RXFP3 Antibody (C-term) Blocking Peptide - Images

RXFP3 Antibody (C-term) Blocking Peptide - Background

RXFP3 is a receptor for RNL3/relaxin-3. Binding of the ligand inhibit cAMP accumulation.

RXFP3 Antibody (C-term) Blocking Peptide - References

Huang, Y.W., et al. Gynecol. Oncol. 117(2):239-247(2010)van der Westhuizen, E.T., et al. Mol. Pharmacol. 77(5):759-772(2010)Hossain, M.A., et al. Chem Biol Drug Des 73(1):46-52(2009)Zhu, J., et al. Eur. J. Pharmacol. 590 (1-3), 43-52 (2008) :Hossain, M.A., et al. J. Biol. Chem. 283(25):17287-17297(2008)